Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia.
Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia.
复制标题
功能加倍：B 细胞急性淋巴细胞白血病中的双特异性酪氨酸调节激酶 1A (DYRK1A)。
DOI：
10.1172/jci142627
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Resar,LindaMs
中科院分区：
文献类型：
--
作者：
Kim,Jung-Hyun;Li,Liping;Resar,LindaMs
正如Bhansali、Rammohan及其同事在本期JCI中报道的那样，DYRK 1A，一种双特异性激酶，再次在功能上加倍。DYRK 1A是一种进化上保守的蛋白激酶，具有双重特异性;它将磷酸盐添加到不同调节蛋白的丝氨酸/苏氨酸残基，并通过自磷酸化激活环中321位的关键酪氨酸来激活其自身功能。Bhansali、Rammohan及其同事研究了唐氏综合征（DS）患者和以非整倍体为特征的白血病儿童的B细胞急性淋巴细胞白血病（B-ALL）。该研究揭示了B-ALL中的DYRK 1A/FOXO 1和STAT 3信号通路，可以靶向治疗，从而为患有或不患有DS的白血病患者的治疗策略打开了大门。
DYRK1A, the dual-specificity kinase, is again doubling up on function, as reported by Bhansali, Rammohan, and colleagues in this issue of theJCI. DYRK1A is an evolutionarily conserved protein kinase with dual specificity; it adds phosphates to serine/threonine residues of diverse regulatory proteins and activates its own function by autophosphorylating a critical tyrosine at position 321 in the activation loop. Bhansali, Rammohan, and colleagues investigated B cell acute lymphoblastic leukemia (B-ALL) in individuals with Down syndrome (DS) and in children with leukemia characterized by aneuploidy. The study revealed a DYRK1A/FOXO1 and STAT3 signaling pathway in B-ALL that could be targeted pharmacologically, thus opening the door to therapeutic strategies for patients with leukemia with or without DS.